Teva Faces Infringement Suits Over TriCor Patent

Law360, New York (March 3, 2008, 12:00 AM EST) -- Brussels-based drug manufacturer Solvay Pharmaceuticals has filed patent infringement lawsuits to stop Teva Pharmaceuticals from selling a generic version of cholesterol drug TriCor – a move that will likely prompt additional antitrust counterclaims against Solvay.

Solvay announced on Monday that its subsidiaries Fournier Laboratories Ireland Ltd. and Laboratoires Fournier SA had filed court actions in the U.S. over Teva's Abbreviated New Drug Application to market a generic version of TriCor 145 mg NFE tablets. Solvay did not say where or when the lawsuits were filed regarding...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.